Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nalbuphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 1.00 |
| ▸ | OPRK1 known ✓ | P41145 | 10/20 | 1.00 |
| ▸ | OPRD1 known ✓ | P41143 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalbuphine SCHEMBL4138643 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118641 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL3118636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL12945211 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL13225650 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL19199045 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL16310791 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL17168336 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL21090866 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 | |
| Nalbuphine SCHEMBL4545390 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005791-B2 | O-demethylating process of methoxy substituted morphinan-6-one derivatives | NORAMCO GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20170022211-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | CILAG AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-8853401-B2 | Processes for the preparation of morphinane and morphinone compounds | BROCK UNIVERSITY (CA) | 2014-10-07 | — | — | US | disclosed |
| US-8524904-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524904-B2 | Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates | MALLINCKRODT LLC (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2180000-B1 | Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates | MALLINCKRODT LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20120046465-A1 | Processes for the Preparation of Morphinane and Morphinone Compounds | BROCK UNIVERSITY (CA) | 2012-02-23 | — | — | US | disclosed |
| US-20120046465-A1 | Processes for the Preparation of Morphinane and Morphinone Compounds | BROCK UNIVERSITY (CA) | 2012-02-23 | — | — | US | disclosed |
| EP-2189460-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES | Mallinckrodt Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | MALLINCKRODT INC. (US) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022211-A1 | O-DEMETHYLATING PROCESS OF METHOXY SUBSTITUTED MORPHINAN-6-ONE DERIVATIVES | TET2, ALKBH5, METTL3 | OPRM1 101/4885OPRK1 404/4885OPRD1 251/4885 |
| US-20120046465-A1 | Processes for the Preparation of Morphinane and Morphinone Compounds | OPRM1, SRM, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 4/4885 |
| US-10005791-B2 | O-demethylating process of methoxy substituted morphinan-6-one derivatives | TET2, ALKBH5, METTL3 | OPRM1 111/4885OPRK1 430/4885OPRD1 277/4885 |
| US-20100081818-A1 | Process for the Preparation of 6-Alpha-Hydroxy-N-Alkylated Opiates | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.